Related Experiment Video
Updated: Jun 6, 2025
A Zebrafish Embryo Model for In Vivo Visualization and Intravital Analysis of Biomaterial-associated Staphylococcus aureus Infection
Published on: January 7, 2019
The proline-rich antimicrobial peptide B7-005: low bacterial resistance, safe for human cells and effective in
Adriana Di Stasi1, Sara Bozzer1, Sabrina Pacor1
1Department of Life Sciences, University of Trieste, 34127 Trieste, Italy.
Abstract:
Proline-rich antimicrobial peptides (PrAMPs) have gained attention due to their antimicrobial properties and low cytotoxicity. B7-005, a small optimized PrAMP, exhibits a broader spectrum of activity than native PrAMPs, due to an antimicrobial mechanism based on inhibiting prokaryotic protein synthesis and destabilizing bacterial membranes. However, the toxicity and the in vivo efficacy of B7-005 remain poorly understood, so in vitro and in vivo microbiology and toxicology experiments were used to assess its suitability as an anti-infective agent. The incidence of resistance towards B7-005 by E. coli was lower than for other PrAMPs and antibiotics; moreover, it maintained antimicrobial activity in the presence of human serum. B7-005 exerted its antimicrobial effect at a much lower concentration than those causing harmful effects on four different cell types, such as membrane permeabilization or non-lytic depolarization of mitochondria. The latter effect may be related to the inhibition of eukaryotic protein synthesis by B7-005 observed in vitro. In a zebrafish embryo model, B7-005 was well tolerated and reduced mortality from pre-existing E. coli bacteraemia. Overall, B7-005 was safe for human cells and effective against systemic infection in vivo, making it a promising lead for developing new antibiotics.
Insights
B7-005, a proline-rich antimicrobial peptide (PrAMP), shows broad-spectrum activity and low toxicity. This optimized peptide effectively combats bacterial infections in vivo with reduced resistance development, making it a promising antibiotic candidate.
Area of Science:
- Microbiology
- Toxicology
- Pharmacology
Background:
- Proline-rich antimicrobial peptides (PrAMPs) are recognized for antimicrobial properties and low cytotoxicity.
- Optimized PrAMP B7-005 demonstrates enhanced activity compared to native PrAMPs.
- The mechanism involves inhibiting prokaryotic protein synthesis and destabilizing bacterial membranes.
Purpose of the Study:
- To evaluate the toxicity and in vivo efficacy of the optimized PrAMP B7-005.
- To assess B7-005's potential as an anti-infective agent.
- To investigate resistance development and activity in human serum.
Main Methods:
- In vitro and in vivo microbiology assays.
- Toxicology experiments on four different cell types.
- Zebrafish embryo model for in vivo efficacy.
- E. coli resistance development studies.
Main Results:
- B7-005 exhibited lower resistance incidence in E. coli compared to other PrAMPs and antibiotics.
- Antimicrobial activity was maintained in the presence of human serum.
- B7-005 showed a wide safety margin, with antimicrobial effects occurring at concentrations far below toxic levels.
- In zebrafish, B7-005 was well-tolerated and reduced mortality from E. coli bacteremia.
- Inhibition of eukaryotic protein synthesis was observed in vitro.
Conclusions:
- B7-005 is safe for human cells and effective against systemic infections in vivo.
- The peptide demonstrates a favorable safety profile and potent antimicrobial activity.
- B7-005 represents a promising lead compound for novel antibiotic development.
